Michael Wasserman, Ph.D. (H. I. G Ventures and Director, Clarus Therapeutics, Inc.). Dr. Wasserman focuses on investments in therapeutics and medical devices. He is involved in all stages of the investment process and currently serves as a board member or observer for H.I.G. portfolio companies HyperBranch Medical Technology, Tranzyme Pharma, CardioFocus, and Metastatix. Prior to joining H.I.G., Dr. Wasserman was a Principal at Innovations Foundation, a firm focused on the creation, financing and growth of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, he was instrumental in building multiple high growth companies based on technology derived from academic or federally sponsored research programs. He has also held prominent operating roles in several entrepreneurial and venture-backed life sciences companies, including CELLutions Biosystems, where he served as Vice President, Business Development. At CELLutions, Dr. Wasserman broadly managed business operations and was directly responsible for the successful negotiation of multiple partnership, co-development and licensing agreement deals with industry leading pharmaceutical and biotechnology organizations. He received his B.Sc. from McGill University and his Ph.D. from the University of Toronto.

H. I. G. Ventures

<< Back